---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-034185"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2026-07-22T12:35:29+00:00"
generated_at: "2026-07-22T12:40:07.207708+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kairos Pharma collaborates with Bayer to test ENV-105 + XOFIGO in mCRPC; market up to $1.3B

## Summary
- Bayer to supply radium for Kairos' study of ENV-105 (carotuximab) with XOFIGO in metastatic castration-resistant prostate cancer.
- Prior Phase 2 data showed 86% clinical benefit rate and median PFS >13 months in resistant mCRPC.
- Addressable global market estimated at $570M–$1.3B.
- ENV-105 targets CD105 to re-sensitize tumors; XOFIGO is FDA-approved alpha-emitting radiopharmaceutical.
- Collaboration includes customary terms; Kairos responsible for study financing and management.

## SEC filing metadata
- accession: 0001493152-26-034185
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2026-07-22T12:35:29+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000149315226034185/0001493152-26-034185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000149315226034185/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-034185
- JSON: https://secwatch.observer/filing/0001493152-26-034185.json
- Plain text: https://secwatch.observer/filing/0001493152-26-034185.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.